Krystexxa resubmission for gout on track for first quarter
15 January 2010
Katie McQue
Please Login to read the full article.
15 January 2010
Katie McQue
katie.mcque@informa.com
Savient Pharmaceuticals says that it is on track to re-file the BLA seeking an indication in chronic and treatment-failure gout for Krystexxa (pegloticase) in the first quarter of this year. It received a complete response letter for the drug from the US FDA last July.
Once submitted, the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Krystexxa launch in motion, as Savient touts gout drug for "an unmet medical need", but concedes ramp-up may be slow
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
- Synageva makes public spectacle with $60 million stock offer after Trimeris merger
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
